Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu dopisy
Grantová podpora
Sanofi
PubMed
38685598
DOI
10.1111/dom.15609
Knihovny.cz E-zdroje
- Klíčová slova
- fixed‐ratio combination, iGlarLixi, insulin glargine and lixisenatide, pooled analysis, prior insulin use, type 2 diabetes,
- MeSH
- diabetes mellitus 2. typu * farmakoterapie MeSH
- fixní kombinace léků MeSH
- glykovaný hemoglobin analýza účinky léků metabolismus MeSH
- hypoglykemika * terapeutické užití MeSH
- inzulin glargin * terapeutické užití aplikace a dávkování MeSH
- krevní glukóza účinky léků metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidy * terapeutické užití aplikace a dávkování MeSH
- receptor pro glukagonu podobný peptid 2 MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- Názvy látek
- fixní kombinace léků MeSH
- glykovaný hemoglobin MeSH
- hemoglobin A1c protein, human MeSH Prohlížeč
- hypoglykemika * MeSH
- inzulin glargin * MeSH
- krevní glukóza MeSH
- lixisenatide MeSH Prohlížeč
- peptidy * MeSH
- receptor pro glukagonu podobný peptid 2 MeSH
Department of Internal Medicine Centrum Szent János Hospital Budapest Hungary
General Medicines Sanofi Paris France
Institute of Clinical Trials and Methodology University College London London UK
International Drug Development Institute Ottignies Louvain la Neuve Belgium
Zobrazit více v PubMed
ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycaemic treatment: standards of care in diabetes‐2023. Diabetes Care. 2023;46(Suppl 1):S140‐S157.
Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669‐2701.
Skolnik N, Del Prato S, Blonde L, Galstyan G, Rosenstock J. Translating iGlarLixi evidence for the management of frequent clinical scenarios in type 2 diabetes. Adv Ther. 2021;38(4):1715‐1731.
Meece J. Basal insulin intensification in patients with type 2 diabetes: a review. Diabetes Ther. 2018;9(3):877‐890.
Bilic‐Curcic I, Cigrovski Berkovic M, Bozek T, Simel A, Klobucar Majanovic S, Canecki‐Varzic S. Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi‐centric observational study. Eur Rev Med Pharmacol Sci. 2022;26(8):2782‐2793.
European Medicines Agency. Suliqua: EPAR – Product information. 2023. https://www.ema.europa.eu/en/documents/product‐information/suliqua‐epar‐product‐information_en.pdf
Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed‐ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan‐O randomized trial. Diabetes Care. 2016;39(11):2026‐2035.
Davies MJ, Russell‐Jones D, Barber TM, et al. Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial. Diabetes Obes Metab. 2019;21(8):1967‐1972.
Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP‐1 RA in type 2 diabetes inadequately controlled by GLP‐1 RA and oral antihyperglycemic therapy: the LixiLan‐G randomized clinical trial. Diabetes Care. 2019;42(11):2108‐2116.
Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed‐ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan‐L randomized trial. Diabetes Care. 2016;39(11):1972‐1980.
Kis JT, Nagy G, Kovacs G. Effectiveness of iGlarLixi, a fixed‐ratio combination of insulin glargine 100 U/mL and lixisenatide, in people with type 2 diabetes. Diabetes Ther. 2021;12(9):2517‐2529.
Bala C, Cerghizan A, Mihai BM, Moise M, Guja C. Real‐world evidence on the use of a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro). BMJ Open. 2022;12(5):e060852.
Haluzík M, Seufert J, Guja C, et al. Effectiveness and safety of iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) in type 2 diabetes according to the timing of daily administration: data from the REALI pooled analysis. Diabetes Ther. 2023;14(4):639‐652.
Freemantle N, Bonadonna RC, Gourdy P, et al. Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project. BMJ Open. 2020;10(4):e033659.
